PubMed HealthSearch

PubMed · 7009096

Substrate utilization by the lung.

Abstract

Intermediary metabolism of the lung and its regulation have received relatively little attention in the past, partly because of difficulty in producing suitable models for study. An in situ perfused rat lung preparation is described which remains viable for four hours or more. Concentration-dependent glucose utilization has been found with this model, associated with marked lactate production. More than half the glucose used appears as lactate, despite the high PO2 and maintenance of normal ATP concentrations. The high rates of glycolysis may be related to glycerol-3-phosphate requirements for lipid synthesis. Glucose clearance from the perfusion medium is dependent on nutritional status, clearance by lungs from 48-hour starved animals being decreased by comparison with lungs of fed controls. Lactate is taken up actively at concentrations of 2 mmol/l or above but is produced at an initial lactate concentration of 0.4 mmol/l. Non-esterified fatty acids (1 mmol/l in the perfusate) are also cleared by lung and may be important as an energy source even though 80% is used for synthetic reactions. Alanine, glycerol and 3-hydroxybutyrate are unimportant as substrates. The lung responds to metabolically important hormones. Insulin and adrenaline cause an acute increase in glucose utilization whereas corticosterone and noradrenaline are inhibitory. Utilization of glucose is also diminished in lungs from diabetic ketoacidotic rats. Further work is required to establish the relative importance of oxidative and synthetic routes for added substrates and the mechanisms of hormonal regulation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Datta, W A Stubbs, K G Alberti. 1980. Substrate utilization by the lung.. https://doi.org/10.1002/9780470720615.ch5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The human mitochondrial genome contains a second light strand promoter.

The human mitochondrial genome must be replicated and expressed in a timely manner to maintain energy metabolism and supply cells with adequate levels of adenosine triphosphate. Central to this process is the idea that replication primers and gene products both arise via transcription from a single light strand promoter (LSP) such that primer formation can influence gene expression, with no consensus as to how this is regulated. Here, we report the discovery of a second light strand promoter (LSP2) in humans, with features characteristic of a bona fide mitochondrial promoter. We propose that the position of LSP2 on the mitochondrial genome allows replication and gene expression to be orchestrated from two distinct sites, which expands our long-held understanding of mitochondrial gene expression in humans.

Adenosine Triphosphate

GCN2 kinase activation by ATP-competitive kinase inhibitors.

Small-molecule kinase inhibitors represent a major group of cancer therapeutics, but tumor responses are often incomplete. To identify pathways that modulate kinase inhibitor response, we conducted a genome-wide knockout (KO) screen in glioblastoma cells treated with the pan-ErbB inhibitor neratinib. Loss of general control nonderepressible 2 (GCN2) kinase rendered cells resistant to neratinib, whereas depletion of the GADD34 phosphatase increased neratinib sensitivity. Loss of GCN2 conferred neratinib resistance by preventing binding and activation of GCN2 by neratinib. Several other Food and Drug Administration (FDA)-approved inhibitors, such erlotinib and sunitinib, also bound and activated GCN2. Our results highlight the utility of genome-wide functional screens to uncover novel mechanisms of drug action and document the role of the integrated stress response (ISR) in modulating the response to inhibitors of oncogenic kinases.

Adenosine Triphosphate